JDG: H1 revenue dropped 21% but order intake rebounded, supporting full-year guidance amid execution risks

Less than 1 min read

Revenue fell 21% year-over-year in H1 2026, with adjusted EPS down 72% amid U.S. funding and China delays. Order intake momentum improved by Q3, supporting full-year guidance, while cost controls and dividend growth continued. Execution risk remains due to Q4 revenue weighting.

Based on [Judges Scientific plc [JDG] H1 2026 Audio Transcript — Sep. 23 2026](https://www.tradingview.com/symbols/LSE-JDG/documents/)

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.